Investigating the oncogenic role of aberrant EZH2 in hepatoblastoma
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Feb 2026 · 1 min read
In brief
In brief
This study identifies EZH2 overexpression as a key driver in hepatoblastoma progression, particularly in aggressive embryonal subtypes. Using single-nuclear RNA sequencing and functional studies, researchers demonstrate that EZH2 inhibition reduces tumor proliferation and enhances cisplatin sensitivity, establishing EZH2 as a promising therapeutic target for this common pediatric liver malignancy.
Written by the GCMD Library team from the article.
Statements in this article
Hepatoblastoma is the most common pediatric liver malignancy.
Single-nuclear RNA sequencing identified a proliferative, hepatocyte-derived tumor cell population enriched for EZH2 expression, particularly in the aggressive embryonal subtype.
Disruption of the PRC2 complex was evident through mislocalization and reduced expression of SUZ12, a core component.
EZH2 overexpression correlated with upregulation of mitotic regulators such as AURKB and Ki67 in human hepatoblastoma compared to background liver.
Targeted sequencing identified variants of uncertain significance in EZH2 and SUZ12 in 11 of 11 patient tumors.
Pharmacologic inhibition of EZH2 with EPZ-6438 reduced proliferation and sensitized hepatoblastoma cells to cisplatin through gene regulation both in vitro and in vivo.
EZH2 promotes hepatoblastoma progression through epigenetic silencing and noncanonical signaling pathways.